April 2017

NEW YORK, April 27, 2017 /PRNewswire/ — According to a report published by Grand View Research, the global medical cannabis market is expected to grow from $11.4 billion in 2015 to $55.8 billion by 2025, with a compound annual growth rate of 17.1 percent during the forecast period. The report claims that the increasing number […]

by

VANCOUVER, British Columbia, April 25, 2017 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (KALY.V), a clinical-stage biopharmaceutical company developing next-generation cannabinoid-derived therapeutics, today announced that it has developed the multi-center location component of the plan for the proposed clinical trials to evaluate cannabidiol (“CBD”) for the prevention and treatment of Graft versus Host Disease (“GvHD”). Kalytera […]

by

Cannabidiol (CBD) is one of at least 113 active cannabinoids identified in cannabis. Unlike the compound tetrahydrocannabinol (THC), CBD is not psychoactive and has significant medical benefits. According to Hemp Business Journal, the total retail value of hemp products sold in the U.S. in 2016 reached $688 million, while the growth of Hemp CBD contributed significantly […]

by

NT: As a cyclone bears down on Australia, memories turn to Darwin 1974. exit RELATED:Tourist dies in crash: Debbie ‘to be worse than Yasi’ It was a miracle fewer than 100 people died from a population of nearly 40,000 when Cyclone Tracy barreled into Darwin on Christmas eve in 1974. As Cyclone Debbie today bears down […]

by

The Weed Blog is excited to announce that one of Oregon’s premier cannabis farms, Yerba Buena, has created and released their highest testing CBD strain, “Corazon” (Spanish for “Heart”). This new highest testing CBD strain is a cross between Charlotte’s Web and AC/DC. Testing at 22.5% CBD and 2.71% THC by Pixis Labs under Oregon’s ORELAP-certified […]

by

Maxim Group started coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a report released on Thursday. The brokerage issued a buy rating and a $135.00 price objective on the biopharmaceutical company’s stock. “Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are inadequately controlled […]

by

LONDON, March 29, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW’s investigational product Epidiolex® (cannabidiol or CBD) […]

by

VANCOUVER, British Columbia, April 25, 2017 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (KALY.V), a clinical-stage biopharmaceutical company developing next-generation cannabinoid-derived therapeutics, today announced that it has developed the multi-center location component of the plan for the proposed clinical trials to evaluate cannabidiol (“CBD”) for the prevention and treatment of Graft versus Host Disease (“GvHD”). Kalytera […]

by